Clinical Trial: A Phase 1/2 Trial of ADI-212 in mCRPC

U.S., Aug. 29 -- ClinicalTrials.gov registry received information related to the study (NCT07793435) titled 'A Phase 1/2 Trial of ADI-212 in mCRPC' on Aug. 26.

Brief Summary: This is a Phase 1/2 multicenter, open-label, dose finding and dose expansion study of ADI-212 in participants with metastatic castration-resistant prostate cancer (mCRPC)

Study Start Date: Sept., 2026

Study Type: INTERVENTIONAL

Condition: PSMA-positive Metastatic Castration-resistant Prostate Cancer (mCRPC)

Intervention: DRUG: ADI-212

Allogeneic cell therapy

DRUG: Fludarabine

Chemotherapy for Lymphodepletion

DRUG: Cyclophosphamide

Chemotherapy for Lymphodepletion

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Adicet Therapeutics

Disclaimer: Curated by H...